HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

STO 609

structure in first source

Also Known As:

7H-benzimidazo(2,1-a)benz(de)isoquinoline-7-one-3-carboxylic acid; STO-609; STO609

Networked: 15 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sankar, Uma: 2 articles (01/2018 - 07/2013)
2.	Voor, Michael J: 2 articles (01/2018 - 07/2013)
3.	Coarfa, Cristian: 2 articles (01/2017 - 08/2015)
4.	Dean, Adam: 2 articles (01/2017 - 08/2015)
5.	Lin, Fumin: 2 articles (01/2017 - 08/2015)
6.	Marcelo, Kathrina L: 2 articles (01/2017 - 08/2015)
7.	Means, Anthony R: 2 articles (01/2017 - 08/2015)
8.	York, Brian: 2 articles (01/2017 - 08/2015)
9.	Allen, M R: 1 article (01/2022)
10.	Burr, D B: 1 article (01/2022)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 01/01/2017 - "Utilizing these data, we show STO-609 treatment to inhibit CaMKK2 function confers protection against non-alcoholic fatty liver disease. " 01/01/2017 - "Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD."
2.	Liver Neoplasms (Liver Cancer) 08/01/2015 - "Cellular ablation of CaMKK2 using RNA interference yields a gene signature that correlates with improvement in HCC patient survival, and ablation or pharmacological inhibition of CaMKK2 with STO-609 impairs tumorigenicity of liver cancer cells in vivo. "
3.	Bone Fractures (Bone Fracture) 01/01/2018 - "In the current study, we investigated the role of CaMKK2 in bone fracture healing and show that its pharmacological inhibition using STO-609 accelerates early cellular and molecular events associated with endochondral ossification, resulting in a more rapid and efficient healing of the fracture. "
4.	Pituitary Neoplasms (Pituitary Adenoma) 01/01/2020 - "Our study is to identify DEGs (Differentially Expressed Genes), comprehensively investigate hub genes, annotate enrichment functions and key pathways of Non-functional pituitary adenomas (NFPAs), and also to verify STO-609 therapeutic effect. " 01/01/2020 - "Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609."
5.	Stomach Neoplasms (Stomach Cancer) 01/01/2021 - "Treatment of gastric cancer cell lines with a CAMKK2 inhibitor, STO-609, resulted in decreased cell migration, invasion, and colony-forming ability and a G1/S-phase arrest. " 01/01/2016 - "Interestingly, we found such effects of STO-609 on gastric cancer cells were not affected after the knock-down of CaMKK-β and AMPK. "

Related Drugs and Biologics

1.	Therapeutic Uses
2.	Calcium-Calmodulin-Dependent Protein Kinase Kinase
3.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
4.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Small Interfering RNA (siRNA)
7.	Collagen Type I (Type I Collagen)
8.	RNA (Ribonucleic Acid)
9.	Protein Kinases (Protein Kinase)
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)
2.	Injections